Department of Laboratory Medicine, Liuzhou People's Hospital, Liu Zhou, China.
Liuzhou Key Laboratory of Precision Medicine for Viral Diseases, Liu Zhou, China.
J Cancer Res Clin Oncol. 2023 Jan;149(1):423-439. doi: 10.1007/s00432-022-04432-0. Epub 2022 Nov 15.
MicroRNAs (miRNAs) are a class of non-coding RNAs that perform post-transcriptional gene regulation. This review focuses on the role of tumor cell-derived miRNAs in the regulation of the tumor microenvironment (TME) via receptor cell recoding, including angiogenesis, expression of immunosuppressive molecules, formation of radiation resistance, and chemoresistance. Furthermore, we discuss the potential of these molecules as adjuvant therapies in combination with chemotherapy, radiotherapy, or immunotherapy, as well as their advantages as efficacy predictors for personalized therapy. MiRNA-based therapeutic agents for tumors are currently in clinical trials, and while challenges remain, additional research on tumor-derived miRNAs is warranted, which may provide significant clinical benefits to cancer patients.
微小 RNA（miRNA）是一类非编码 RNA，通过受体细胞重编码来执行转录后基因调控。本综述重点讨论了肿瘤细胞衍生的 miRNA 在调节肿瘤微环境（TME）方面的作用，包括血管生成、免疫抑制分子的表达、辐射抗性和化学抗性的形成。此外，我们还讨论了这些分子作为辅助治疗与化疗、放疗或免疫治疗联合应用的潜力，以及它们作为个性化治疗疗效预测因子的优势。目前正在进行基于 miRNA 的肿瘤治疗剂的临床试验，尽管仍存在挑战，但需要对肿瘤衍生的 miRNA 进行更多的研究，这可能会为癌症患者带来显著的临床获益。
